公开(公告)号：US20170145020A1

公开(公告)日：2017-05-25

申请号：US15424536

申请日：2017-02-03

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-Wei Yuen

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61P11/06 ,  C07D403/14 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20230167123A1

公开(公告)日：2023-06-01

申请号：US18063575

申请日：2022-12-08

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Grandner ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61P37/06

Abstract: Compounds of formula (I)




wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20220204517A1

公开(公告)日：2022-06-30

申请号：US17654131

申请日：2022-03-09

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Paul Gibbons ,  Terry Kellar ,  Wei Li ,  Rohan Mendonca ,  Po-wai Yuen ,  Mark Edward Zak ,  Lei Zhang

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20220106322A1

公开(公告)日：2022-04-07

申请号：US17644742

申请日：2021-12-16

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Wei Li ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US11155557B2

公开(公告)日：2021-10-26

申请号：US16452058

申请日：2019-06-25

Applicant: Genentech, Inc.

Inventor： F. Anthony Romero ,  Mark Zak ,  Guiling Zhao ,  Paul Gibbons ,  Wei Li ,  Yun-Xing Cheng ,  Po-Wai Yuen ,  Limin Cheng

IPC: C07D487/04 ,  C07D498/10

Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20190337946A1

公开(公告)日：2019-11-07

申请号：US16515253

申请日：2019-07-18

Applicant: Genentech, Inc.

Inventor： Simon Charles Goodacre ,  Nicholas Charles Ray ,  Mark Edward Zak ,  Yun-Xing Cheng ,  Wei Li

IPC: C07D471/04 ,  C07D471/10

Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.

公开(公告)号：US20190322661A1

公开(公告)日：2019-10-24

申请号：US16438135

申请日：2019-06-11

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-wai Yuen

IPC: C07D471/04 ,  C07D487/04 ,  C07D403/14 ,  A61K31/519 ,  C07D519/00 ,  A61P11/06

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20180265515A1

公开(公告)日：2018-09-20

申请号：US15986256

申请日：2018-05-22

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Paul Gibbons ,  Terry Kellar ,  Wei Li ,  Rohan Mendonca ,  Po-wai Yuen ,  Mark Edward Zak ,  Lei Zhang

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US09604984B2

公开(公告)日：2017-03-28

申请号：US15139164

申请日：2016-04-26

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-Wei Yuen

IPC: C07D487/04 ,  A61K31/519 ,  A61P11/06 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.